Cite
HARVARD Citation
Xu, C. et al. (2017). Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review. Thoracic cancer. 8 (6), pp. 714-719. [Online].